entertainment -WSS

entertainment

author：focus 2025-09-05 13:45:59 - browse：7985

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Inari Medical to buy amputation prevention company LimFlow

entertainment

leisure time

WSS

Humans aren't the only ones with an imagination. Rats have it too

FTC falls short on scrutinizing hospital mergers, study says

Life sciences investors close nearly $6 billion in new funds

FTC falls short on scrutinizing hospital mergers, study says

Key Senate committee drafts bipartisan bill to stem drug shortages

Readout LOUD podcast: ESMO highlights & Roivant's big deal

explore

entertainment

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Kidney transplant patients stopped immunosuppressants in trial

New air purifier tech could be key to improving indoor air quality

Medicare must police algorithms in Medicare Advantage, Dems say

Heart attack and stroke risk calculators need revising

Orangutan used medicinal plant to treat wound, first time ever seen

Bright Health sells Medicare Advantage business to Molina

Gene therapy’s promise and the high cost of hope

Medicare proposal to cover medical devices draws a mixed reaction

How to convince healthy people to buy insurance

hotspot

Live blog: Hearing on CRISPR

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

After traumatic brain injury, life support decisions can use more time

Cholera vaccine supply gets boost as demand surges globally

Prime Medicine says its gene editing passes test in monkeys

Humans aren't the only ones with an imagination. Rats have it too

entertainment

focus

leisure time

entertainment